The Trump administration's decision to impose a 100% tariff on imported patented drugs, with Australian pharmaceuticals facing the highest rate, has sparked concern among the Albanese government and opposition. However, Australia's largest biotech firm, CSL, may be exempt or face a lower tariff rate due to carve-outs for certain products and countries. This move, aimed at re-shoring US pharmaceutical production, has significant implications for the industry and global trade dynamics.
The 100% tariff, with exceptions for some countries, is a bold move by President Trump, who signed an executive order on Thursday. The standard rate is 100%, but countries like the European Union, Japan, South Korea, and Switzerland receive a 15% discount. Australia, despite its long-standing free trade agreement, does not have a special tariff rate, raising concerns about the impact on local drugmakers.
One of the key aspects of this decision is the potential exemption for CSL, which has operations in the US, Australia, and Europe. The company's recent expansion in the US, with a $1.5 billion investment, could be crucial in meeting the new tariff requirements. A White House official stated that CSL must submit its plan to the US Commerce Department, which has the discretion to grant exemptions, highlighting the importance of CSL's role in this scenario.
The executive order also includes a provision for plasma-derived therapies, which constitute a significant portion of CSL's trade into the US. These therapies will be exempt from the tariff if they come from a country with a trade deal with the US or meet an urgent US health need. This carve-out is seen as a strategic move to ensure access to essential medical treatments.
The Albanese government and opposition have expressed disappointment, with the Trade Minister and Health Minister emphasizing the impact on Australian drugmakers and the Pharmaceutical Benefits Scheme (PBS). The opposition leader, Angus Taylor, supports free trade and is committed to working with the government to secure exemptions for Australian exporters.
The timing of the tariff announcement, one year after Trump's 'Liberation Day' tariffs, is significant. The pharmaceutical tariffs are distinct, enacted under Section 232 of the Trade Expansion Act, and were not covered by the US Supreme Court's ruling that found the previous tariffs unlawful. This move is part of a broader strategy to reshape US trade policies and protect domestic industries.
In conclusion, the Trump administration's pharmaceutical tariffs have far-reaching consequences, impacting global trade and the pharmaceutical industry. The carve-outs for certain products and countries, including the potential exemption for CSL, demonstrate the complexity of the situation. As the industry adapts to these changes, the future of global pharmaceutical trade and the role of countries like Australia remain uncertain.
